FASIHA KANWAL to Drug Therapy, Combination
This is a "connection" page, showing publications FASIHA KANWAL has written about Drug Therapy, Combination.
Connection Strength
0.675
-
Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
Score: 0.141
-
Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Dig Dis Sci. 2019 11; 64(11):3328-3336.
Score: 0.116
-
Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018 11; 25(11):1270-1279.
Score: 0.110
-
The end of hepatitis C. Clin Gastroenterol Hepatol. 2014 Apr; 12(4):533-6.
Score: 0.081
-
Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012 Jan 01; 54(1):96-104.
Score: 0.070
-
Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006 May; 119(5):448.e27-36.
Score: 0.047
-
Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol. 2004 Sep; 99(9):1726-32.
Score: 0.042
-
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance. Ann Hepatol. 2023 Mar-Apr; 28(2):100899.
Score: 0.038
-
Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020 02; 174:104698.
Score: 0.030